Biotechnology News and Research

RSS

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class anti-infectives for the treatment and prevention of antibiotic-resistant infections, today reported positive results of an open-label Phase 2a trial of NVC-422 in chronically catheterized patients with significant bacteriuria, or bacteria in the urine. The study showed that NVC-422 was well tolerated and reduced or eliminated certain pathogens in the urine.

15 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Foundation Medicine, a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis into routine clinical care, today announced it has completed a $25 million Series A financing led by Third Rock Ventures.

15 Apr 2010

Mach One acquires White Hat Brands

Mach One Corporation, a global wellness solutions company, and White Hat Brands, LLC today announced the two companies have completed a definitive agreement whereby Mach One has acquired 100% interest in the fast-growing maker of kids' health and wellness beverages, including White Hat's top-seller Dog On It® Fortified Juice Beverages.

15 Apr 2010

Cell Therapeutics reduces workforce to cut operating costs

Cell Therapeutics, Inc. today announced it has conducted an immediate reduction in force of 36 employees. The Company expects the reduction in force and elimination of previously planned increase in commercial personnel along with a reduction in planned operating expenses to result in savings of approximately $16 million in 2010.

15 Apr 2010

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cumberland Pharmaceuticals Inc. today announced results from a meta-analysis comparing the efficacy and safety of ibuprofen and acetaminophen, which was published in the March edition of the peer-reviewed journal The Annals of Pharmacotherapy. The publication notes that in a majority of evaluated studies ibuprofen demonstrated superior efficacy compared to acetaminophen for the treatment of pain and fever, and found no significant safety differences between the drugs.

15 Apr 2010

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

Thirty percent of patients surveyed experienced an infection as a result of chemotherapy, 45 percent of which were associated with neutropenia or febrile neutropenia according to findings from a pan-European patient and nurse survey presented today at the 7th Annual European Oncology Nursing Society Spring Convention.

15 Apr 2010

BeaconEquity.com releases investment report featuring Antigenics

BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

The nuts and bolts of reform's new policies

The New York Times: "In a new report, the Congressional Research Service says the law may have significant unintended consequences for the 'personal health insurance coverage' of senators, representatives and their staff members." Lawmakers agreed to depart from their existing health plans in order to join new health insurance exchanges, something they have made available to many of their constituents. But, while the exchanges don't start up until 2014, the law is silent on when lawmakers must ditch their current benefits.

15 Apr 2010

Genomic component playing key role in promoting breast cancer progression discovered

Life Technologies Corporation today announced that its scientists have teamed with researchers from Stanford University School of Medicine, and other institutions to discover a genomic component that plays a key role in promoting breast cancer progression. A study published today in the journal Nature details how levels of a specific kind of non-coding RNA molecule in primary breast tumors regulate metastasis and tumor invasiveness and may be an important target for cancer diagnosis and therapy.

15 Apr 2010

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced interim data from a 14-day, phase IIa clinical trial evaluating IDX184, a novel liver-targeted nucleotide prodrug of 2'-methyl guanosine monophosphate, in HCV-infected patients.

15 Apr 2010

OrbusNeich Medical awarded US patent for "Stent with Helical Elements"

OrbusNeich Medical, Inc., a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of cardiovascular diseases, today announced that on March 23, 2010, the Company was granted U.S. Patent No. 7,682,384 B2, entitled "Stent with Helical Elements." The patent relates to an expandable stent comprised of a plurality of helical segments. The Company noted that it has identified unlicensed use by Boston Scientific Corporation of certain technologies protected under U.S. Patent No. 7,682,384 B2.

15 Apr 2010

Tengion completes initial 6M common stock public offering

Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.

15 Apr 2010

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product.

15 Apr 2010

Successful stem cell therapy performed on CHF patients in Mexico

Bioheart, Inc. announced that treatment with stem cell therapy on two congestive heart failure (CHF) patients was performed successfully at the Hospital Angeles Tijuana, Mexico, through Bioheart's Center of Excellence program with Regenerative Medicine Institute.

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

Beckman Coulter awarded new agreement with Premier Purchasing Partners for laboratory systems and supplies

Beckman Coulter, Inc., a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, announced that effective April 1, 2010, it has been awarded a new agreement with Premier Purchasing Partners, the group purchasing unit of Premier, Inc., to provide a full range of core laboratory systems and supplies. Premier is one of the nation's largest healthcare purchasing networks, with more than 2,300 member hospitals and 64,000 additional healthcare sites.

From Beckman Coulter Diagnostics 15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Patheon adds development and manufacturing softgel capability in Cincinnati facility

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it is adding development and manufacturing softgel capability in its Cincinnati facility, providing the pharmaceutical industry a new contract provider for this popular drug delivery system.

15 Apr 2010

Biotechnology News and Research

Positive results from NovaBay Pharmaceuticals' Phase 2a trial of NVC-422

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Foundation Medicine completes $25M Series A financing led by Third Rock Ventures

Mach One acquires White Hat Brands

Cell Therapeutics reduces workforce to cut operating costs

Ibuprofen demonstrates efficacy over acetaminophen for treatment of pain and fever

Cancer patients continue to be affected by FN as a result of chemotherapy: Survey

BeaconEquity.com releases investment report featuring Antigenics

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

The nuts and bolts of reform's new policies

Genomic component playing key role in promoting breast cancer progression discovered

Interim data from phase IIa clinical trial of IDX184 in HCV-infected patients

OrbusNeich Medical awarded US patent for "Stent with Helical Elements"

Tengion completes initial 6M common stock public offering

John Muir Physician Network to participate in Generex Oral-lyn FDA Expanded Access Treatment IND program

Successful stem cell therapy performed on CHF patients in Mexico

Opexa Therapeutics presents key efficacy data on Tovaxin

Beckman Coulter awarded new agreement with Premier Purchasing Partners for laboratory systems and supplies

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Patheon adds development and manufacturing softgel capability in Cincinnati facility

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News